Skip to main content

Table 1 Baseline characteristics of included patients

From: Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis

First Author Year No. of patients
Treatment/Control
Age(median)
Treatment/Control
Male sex (%) Prior systemic therapy (%)
Treatment/Control Type Treatment Control
PD-1/L1 versus chemotherapy
 Robert 2015 210/208 64/66 57.6/60.1 Adjuvant therapy 15.2 17.3
Neoadjuvant therapy 0.5 0.5
 Weber 2015 272/133 59/62 65/64 Ipilimumab > 99 100
Chemotherapy 53 54
Vemurafenib 18 17
Other immunotherapy 14 26
 Ribas 2015 180/181/179 62/60/63 58/60/64 Ipilimumab 100/100 100
Chemotherapy 50/46 48
Other immunotherapy 37/34 31
CTLA-4 versus chemotherapy
 Ribas 2013 328/327 57/56 58/56 Radiation therapy 2 2
Adjuvant therapy 2 3
CTLA-4 versus placebo
 Eggermont 2015 475/476 51/52 62/62 Surgical therapy 100 100
PD-1/L1 versus CTLA-4
 Schachter 2017 279/277/278 61/63//62 57.7/62.8/58.3 BRAF/MET inhibitor 18/16 20
Immunotherapy 3/3 4.3
Chemotherapy 13/15 10
CTLA-4 plus chemotherapy versus chemotherapy
 Robert C 2011 250/252 58/56 60.8/59.1 Adjuvant therapy 26 27
CTLA-4 plus adjuvant therapy versus CTLA-4 or adjuvant therapy
 Hodi FS 2010 403/137/136 56/57/56 61.3/59.1/53.7 Adjuvant therapy 22 23/24
Systemic therapy 100 100/100
 Hodi FS 2014 123/122 61/64 69.1/63.9 Adjuvant therapy 15 14
Systemic therapy 31 30
CTLA-4 plus PD-1/L1 versus CTLA-4 or PD-1/L1
 Hodi 2016 95/47 64/67 66/68 Not mentioned   
 Larkin 2015 314/315/3161 59/61/59 65.6/64.1/63.9 Not mentioned   
BRAF plus MEK versus BRAF
 Larkin 2014 247/248 56/55 59/56 Not mentioned   
 Long 2014 211/212 55/56.5 53/54 Immunotherapy 27 29
 Robert 2015 352/352 55/54 59/51 Immunotherapy 17 26
MEK plus chemotherapy versus chemotherapy
 McDermott 2008 51/50 55/60 75/66 Surgery 100 100
Radation therapy 29 22
Immunotherapy 67 72
 Hauschild 2009 135/135 56/55.1 62/64 Surgery 100 100
Radation therapy 27 33
Chemotherapy 67 62
Immunotherapy 26 30
 Flaherty 2013 410/413 61/59 66/61 Immunotherapy 37 38
 Robert 2013 45/46 57/52 49/61 Surgery 89 83
Radation therapy 18 26
Chemotherapy 7 2
Immunotherapy 42 48
 Gupta 2014 41/42 62/63 76/64 Not mentioned   
BRAF versus chemotherapy
 McArthur 2014 187/63 53/50 60/59 Radation therapy 20 16
Immunotherapy 28 24
 Hauschild 2012 337/338 56/52.5 59/54 Not mentioned   
MEK versus chemotherapy
 Flaherty 2012 214/208 55/54 56/49 Immunotherapy 32 28
Chemotherapy 67 65
 Kirkwood 2012 104/96 57.1/57 52.9/67.7 Not mentioned   
 Carvajal 2014 50/51 62/62 52/62 Immunotherapy 16 22
\